These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 32649404)

  • 1. The Role of Tocilizumab in the Treatment of Adult-Onset Still Disease-Report of a Tertiary Single-Center Experience.
    Almeida DE; Costa E; Neves JS; Cerqueira M; Ribeiro AR
    J Clin Rheumatol; 2021 Dec; 27(8S):S875-S876. PubMed ID: 32649404
    [No Abstract]   [Full Text] [Related]  

  • 2. Treating Adult-Onset Still Disease With Tocilizumab: A Case-Based Review.
    Rodrigues J; Santos-Faria D; Silva J; Azevedo S; Guimarães F; Esperança Almeida D; Teixeira F; Peixoto D; Alcino S; Afonso C; Tavares-Costa J
    J Clin Rheumatol; 2021 Dec; 27(8S):S414-S415. PubMed ID: 32251045
    [No Abstract]   [Full Text] [Related]  

  • 3. [Not Available].
    Z Rheumatol; 2016 May; 75(4):344-5. PubMed ID: 27095556
    [No Abstract]   [Full Text] [Related]  

  • 4. Long-term safety of tocilizumab treatment on chronic active hepatitis C in a patient with adult onset Still's disease.
    Forestier E; Pasquali JL
    Joint Bone Spine; 2015 Mar; 82(2):136-7. PubMed ID: 25553837
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficacy of tocilizumab in refractory adult-onset Still's disease; report of 2 cases.
    Andrade-Ortega L; Irazoque-Palazuelos F; Muñoz-López S; Rosales-Don Pablo VM
    Reumatol Clin; 2014; 10(3):199-200. PubMed ID: 24076178
    [No Abstract]   [Full Text] [Related]  

  • 6. Tocilizumab in patients with adult-onset still's disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial.
    Kaneko Y; Kameda H; Ikeda K; Ishii T; Murakami K; Takamatsu H; Tanaka Y; Abe T; Takeuchi T
    Ann Rheum Dis; 2018 Dec; 77(12):1720-1729. PubMed ID: 30279267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Tocilizumab effectiveness in adult Still's disease].
    López Buitrago R; Estrada Dorronsoro S; Cervera Segura R; Espinosa Garriga G
    Med Clin (Barc); 2012 Jan; 138(1):42-3. PubMed ID: 21605875
    [No Abstract]   [Full Text] [Related]  

  • 8. Urticarial rash, fever, and arthritis: A case of refractory Adult-onset Still's disease with good response to tocilizumab.
    Wawrzycki B; Krasowska D; Pietrzak A; Wielosz E; Majdan M; Lotti T
    Dermatol Ther; 2019 Sep; 32(5):e13041. PubMed ID: 31361930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tocilizumab for the treatment of adult-onset Still's disease.
    Castañeda S; Martínez-Quintanilla D; Martín-Varillas JL; García-Castañeda N; Atienza-Mateo B; González-Gay MA
    Expert Opin Biol Ther; 2019 Apr; 19(4):273-286. PubMed ID: 30827128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biomarkers for disease flare in patients with adult-onset Still's disease undergoing treatment with tocilizumab.
    Yamada H; Kaneko Y; Tamai H; Takeuchi T
    Rheumatology (Oxford); 2020 Feb; 59(2):440-442. PubMed ID: 31504968
    [No Abstract]   [Full Text] [Related]  

  • 11. Successful tocilizumab therapy in seven patients with refractory adult-onset Still's disease.
    Bannai E; Yamashita H; Kaneko S; Ueda Y; Ozaki T; Tsuchiya H; Takahashi Y; Kaneko H; Kano T; Mimori A
    Mod Rheumatol; 2016; 26(2):297-301. PubMed ID: 24697199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Refractory adult-onset Still's disease].
    Fain O; Rouaghe S; Stirnemann J
    Rev Prat; 2010 Mar; 60(3):314. PubMed ID: 20402117
    [No Abstract]   [Full Text] [Related]  

  • 13. [Adult onset Still's disease with small vessel vasculitis].
    Hoff P; Hoyer BF; Schneider U; Kneitz C; Burmester GR; Buttgereit F
    Z Rheumatol; 2015 Aug; 74(6):540-2. PubMed ID: 26231832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two cases of adult-onset Still's disease treated with tocilizumab that achieved tocilizumab-free remission.
    Kobayashi D; Ito S; Murasawa A; Narita I; Nakazono K
    Intern Med; 2015; 54(20):2675-9. PubMed ID: 26466710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between earlier introduction of tocilizumab and glucocorticoid-sparing effects on the acute phase of adult-onset Still's disease.
    Yoshihara R; Tsuchiya H; Shoda H; Fujio K
    Scand J Rheumatol; 2024 Jul; 53(4):284-287. PubMed ID: 38314790
    [No Abstract]   [Full Text] [Related]  

  • 16. Prolonged treatment with Tadekinig alfa in adult-onset Still's disease.
    Kiltz U; Kiefer D; Braun J; Schiffrin EJ; Girard-Guyonvarc'h C; Gabay C
    Ann Rheum Dis; 2020 Jan; 79(1):e10. PubMed ID: 30352887
    [No Abstract]   [Full Text] [Related]  

  • 17. [CME: Adult Still disease].
    Etter M; Vallelian F; Herfs G
    Praxis (Bern 1994); 2015 Oct; 104(21):1117-25. PubMed ID: 26463902
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy of Low-Dose Tocilizumab on Relapsing Adult-Onset Still's Disease.
    Vandemergel X; Vandergheynst F
    Acta Medica (Hradec Kralove); 2016; 59(1):22-5. PubMed ID: 27131353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patients' experience and tolerability with canakinumab and anakinra for the treatment of adult-onset Still's disease.
    Campochiaro C; Farina N; Tomelleri A; De Luca G; Cavalli G; Dagna L
    Clin Exp Rheumatol; 2022 Sep; 40(8):1598-1599. PubMed ID: 35349406
    [No Abstract]   [Full Text] [Related]  

  • 20. Successful use of short-term add-on tocilizumab for refractory adult-onset still's disease with macrophage activation syndrome despite treatment with high-dose glucocorticoids, cyclosporine, and etoposide.
    Ohmura SI; Uehara K; Yamabe T; Tamechika S; Maeda S; Naniwa T
    Mod Rheumatol Case Rep; 2020 Jul; 4(2):202-207. PubMed ID: 33086994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.